The rolling out of a progamme of immuno-oncology treatments is one of the priorities of the Department of oncology. The aim of such a programme is to offer access to innovative therapies to those patients who have not responded to standard treatments, namely within the context of enrolment in one of its clinical trials.
The Immuno-oncology service is dedicated to early phase clinical research in cancer immunotherapies.
Its vocation is to offer a large portfolio of clinical trials centred on the development of innovative therapies which harness the intrinsic characteristics of the immune system. As such, our immuno-oncology patient care includes:
The cancer-immunity cycle in our sights
A programme of adoptive cellular therapy, based on TIL (tumour-infiltrating lymphocyte) cells, allows us to propose treatments which rationally target the various stages of the cancer-immunity cycle. This is achieved by promoting immunogenicity, the presentation of tumoral antigens, the reactivation and potentiation of T lymphocyte cells, and supporting their entry into the tumour environment.
The therapies draw on a broad spectrum of therapeutic/drug classes being developed, including monoclonal antibodies with inhibitory or agonist activities, modified cytokines or immunocytokines and oncolytic viruses. The intent is to garner a new, lasting and efficient anti-tumour immune equilibrium.
Cellular engineering of tomorrow
In the future, the portfolio will be enriched by other trials, currently under development, based on genetically modified T lymphocyte cells, applicable to hematologic malignancies and solid tumours alike.